Table 2.
Results of surveillance for dapsone (DDS) and ofloxacin (OFL) resistance (R) detailed per country for the study period 2009–15
| Country | Surveillance of dapsone resistance |
Surveillance of ofloxacin resistance |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relapsea |
Newc |
All cases |
Relapsea |
Newc |
All cases |
|||||||
| No. of cases | DDS-Rb | No. of cases | DDS-Rd | No. of cases | DDS-R (%) | No. of cases | OFL-R | No. of cases | OFL-R | No. of cases | OFL-R (%) | |
| Benin | 0 | 0 | 85 | 4 | 85 | 4 (4.7) | 0 | 0 | 85 | 1 | 85 | 1 |
| Brazil | 187 | 25 | 26 | 2 | 213 | 27 (12.7) | 154 | 3 | 23 | 0 | 177 | 3 |
| Burkina Faso | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 0 |
| China | 61 | 6 | 55 | 2 | 116 | 8 (6.9) | 61 | 0 | 55 | 0 | 116 | 0 |
| Colombia | — | — | — | — | — | — | — | — | — | — | — | — |
| Ethiopia | 1 | 0 | 27 | 0 | 28 | 0 | 1 | 0 | 27 | 0 | 28 | 0 |
| Guinea | 1 | 0 | 23 | 4 | 24 | 4 (16.7) | 1 | 0 | 23 | 0 | 24 | 0 |
| India | 241 | 15 | 104 | 7 | 345 | 22 (6.4) | 242 | 10 | 139 | 7 | 381 | 17 |
| Indonesia | 0 | 0 | 70 | 3 | 70 | 3 (4.3) | — | — | — | — | — | |
| Mali | 20 | 1 | 115 | 2 | 135 | 3 (2.2) | 20 | 0 | 115 | 0 | 135 | 0 |
| Madagascar | 13 | 0 | 103 | 1 | 116 | 1 (0.9) | 13 | 0 | 103 | 0 | 116 | 0 |
| Mozambique | 5 | 0 | 0 | 0 | 5 | 0 | 7 | 0 | 0 | 0 | 7 | 0 |
| Myanmar | 106 | 3 | 2 | 0 | 108 | 3 (2.8) | 106 | 0 | 2 | 0 | 108 | 0 |
| Nepal | 39 | 0 | 12 | 0 | 51 | 0 | 54 | 0 | 10 | 0 | 64 | 0 |
| Niger | 17 | 0 | 47 | 1 | 64 | 1 (1.6) | 18 | 0 | 47 | 0 | 65 | 0 |
| Philippines | 43 | 0 | 140 | 4 | 183 | 4 (2.2) | 43 | 0 | 140 | 0 | 183 | 0 |
| Vietnam | 13 | 2 | 62 | 5 | 75 | 7 (9.3) | 13 | 0 | 62 | 0 | 75 | 0 |
| Pakistan | 5 | 0 | 0 | 0 | 5 | 0 | 5 | 0 | 0 | 0 | 5 | 0 |
| Yemen | 8 | 0 | 6 | 0 | 14 | 0 | 8 | 0 | 2 | 0 | 10 | 0 |
| Totals | 762 | 52 | 877 | 35 | 1639 | 87 (5.3) | 748 | 13 | 833 | 8 | 1581 | 21 |
—, not tested.
a
Number of relapse leprosy cases for which result was obtained.
b
Number of resistant cases among relapse cases.
c
Number of new leprosy cases for which result was obtained.
d
Number of resistant cases among new cases.